Intended for healthcare professionals only. The information on this website is not country-specific. This is an international disease awareness campaign.

Home / RheumatoidFactor

The Role of Rheumatoid Factor in Rheumatoid Arthritis

Discover more about the role of rheumatoid factor in rheumatoid arthritis


High rheumatoid factor levels (above 200 IU/ml) are associated with higher probability of radiographic progression9

Learn about recent data and their impact on rheumatoid arthritis clinical management

Watch Webinars Now

What do we know about the role of rheumatoid factor in rheumatoid arthritis?

  • Innate
  • Adaptive

Impact on treatment responses

Higher levels of disease activity

Explore how the structure of rheumatoid factor links to its mechanism of action

Take Me There

Learn more about rheumatoid factor and hear expert insights on how to enhance your clinical practice

Watch Webinars Now

Intended for US Healthcare Professionals only

UCB Medical

Explore scientific information on UCB medicines used to treat immune-mediated inflammatory conditions

Intended for US Healthcare Professionals only


Uncover the mechanisms driving SpA diseases and information about the science of SpA

Intended for EU Healthcare Professionals only


Discover educational resources to enhance your clinical practice


Find out what support is available from UCB to people living with chronic diseases

  1. Abbreviations: EU: European Union; ACR: American College of Rheumatology; ARA: American Rheumatism Association; Fc: fragment crystallizable; Ig: immunoglobulin; SpA: spondyloarthritis; US: United States.
  2. References: 1. Waaler E. APMIS. 2007;115(5):422–38; 2. Ropes MW, et al. Ann Rheum Dis. 1957;16(1):118–25; 3. Edelman GM, et al. J Exp Med. 1958;108(1):105–20; 4. Ragan C, Farrington E. JAMA. 1962;181(8):663–7; 5. Zvaifler NJ. J Clin Invest. 1969;48(8):1532–1542; 6. Arnett FC, et al. Arthritis Rheum. 1988;31(3):315–24; 7. Ingegnoli F, et al. Dis Markers. 2013;35(6):727–34; 8. de Brito Rocha S, et al. Adv Rheumatol. 2019;59(1):2; 9. Vastesaeger N, et al. Rheumatology (Oxford). 2009;48(9):1114–21; 10. Senolt L. F1000Res. 2019;8:F1000 Faculty Rev-1549; 11. Maibom-Thomsen SL, et al. PLoS One. 2019;14(6):e0217624; 12. Levy RA, et al. Immunotherapy. 2016;8(12):1427–36; 13. Aletaha D, et al. Arthritis Res Ther. 2015;17(1):229; 14. Albrecht K, et al. Arthritis Res Ther. 2017;19(1):68; 15. Sobhy N, et al. Egypt Rheumatol. 2022;44(4):325–8; 16. van Zeben D, et al. Ann Rheum Dis. 1992;51(9):1029–35; 17. Cojocaru M, et al. Maedica (Bucur). 2010;5(4):286–91; 18. Nell VPK, et al. Ann Rheum Dis. 2005;64(12):1731–6; 19. England BR, et al. Arthritis Care Res (Hoboken). 2016;68(1):36–45; 20. Katchamart W, et al. Rheumatol Int. 2015;35(10):1693–9.